Rocket Pharmaceuticals (RCKT) Equity Ratio (2014 - 2026)

Rocket Pharmaceuticals has disclosed Equity Ratio across 13 years of filings, most recently posting 0.83 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.83, down 4.67% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.83 (down 4.67% YoY), and the FY2025 annual result was 0.84, down 4.43% from the prior year.
• Equity Ratio came in at 0.83 for Q1 2026 at Rocket Pharmaceuticals, down from 0.84 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.91 in Q1 2022 to a low of 0.83 in Q1 2026.
• The 5-year median for Equity Ratio is 0.87 (2025), against an average of 0.87.
• Across the five-year window, Equity Ratio climbed 9.0% in 2022 and dropped 7.31% in 2024, its largest moves.
• Rocket Pharmaceuticals' Equity Ratio stood at 0.89 in 2022, then slipped by 1.99% to 0.87 in 2023, then advanced by 0.93% to 0.88 in 2024, then slipped by 4.43% to 0.84 in 2025, then declined by 0.58% to 0.83 in 2026.
• The last three Equity Ratio figures came in at 0.83 (Q1 2026), 0.84 (Q4 2025), and 0.85 (Q3 2025), per Business Quant data.